5985-24-0

Usage

Uses

Used in Organic Synthesis:
DIMETHYL 4-HYDROXYISOPHTHALATE is used as a key intermediate for the synthesis of various chemical compounds. Its ester and hydroxyl groups make it a versatile building block in the creation of a wide range of products, including pharmaceuticals, agrochemicals, and specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, DIMETHYL 4-HYDROXYISOPHTHALATE is used as a starting material for the development of new drugs. Its unique chemical structure allows for the creation of novel drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
DIMETHYL 4-HYDROXYISOPHTHALATE is also utilized in the agrochemical industry for the synthesis of various pesticides and other crop protection agents. Its chemical properties enable the development of innovative products that can help improve crop yields and protect against pests and diseases.
Used in Specialty Chemicals:
In the specialty chemicals sector, DIMETHYL 4-HYDROXYISOPHTHALATE is employed in the production of various high-value products, such as dyes, additives, and coatings. Its versatility and reactivity make it an essential component in the formulation of these specialized materials.
Overall, DIMETHYL 4-HYDROXYISOPHTHALATE is a valuable compound with a wide range of applications across different industries, thanks to its unique chemical structure and properties.

InChI:InChI=1/C10H10O5/c1-14-9(12)6-3-4-8(11)7(5-6)10(13)15-2/h3-5,11H,1-2H3

Upstream product

• 186581-53-3 diazomethane 
• 636-46-4 4-hydroxyisophthalic acid 
• 71043-33-9 methyl 2-methoxymethylene-3-oxobutanoate 
• 67-56-1 methanol 
• 577-05-9 1-methoxy-2,4-bis-trifluoromethyl-benzene 
• 34133-58-9 4-hydroxy-isophthalonitrile 
• 619-72-7 4-nitrobenzonitrile 
• 327-76-4 4-chloro-α,α,α,α',α',α'-hexafluoro-m-xylene 
• 105-67-9 2,4-Xylenol 
• 7501-68-0 4-acetamidoisophthalic acid 
• 33890-03-8 4-aminoisophthalic acid 
• 121810-12-6 4-Oxo-5-phenylsulfanyl-cyclohexane-1,3-dicarboxylic acid dimethyl ester 
• 181723-27-3 5-Acetyl-6'-hydroxy-6,2'-dioxo-6H,2'H-[2,3']bipyranyl-5'-carboxylic acid methyl ester 
• 74828-41-4 3,3',5,5'-tetrakismethoxycarbonylglaucyrone 

Downstream Products

• 79128-78-2 2-hydroxy-5-(methoxycarbonyl)benzoic acid 
• 2937-60-2 2,4-bis(hydroxymethyl)phenol 
• 22633-33-6 methyl-3,5-dinitrosalicylate 
• 636-46-4 4-hydroxyisophthalic acid 
• 41684-11-1 4-hydroxy-3-(methoxycarbonyl)benzoic acid 
• 108129-45-9 4-hydroxy-isophthalic acid diamide 
• 63874-38-4 5-methoxycarbonylsalicylamide 
• 98953-42-5 4-hydroxy-isophthalic acid-3-hydrazide-1-methyl ester 
• 102541-30-0 5-chloro-4-hydroxy-isophthalic acid dimethyl ester 
• 54176-51-1 5-bromo-4-hydroxyisophthalic acid dimethyl ester 
• 22235-28-5 4-hydroxy-5-nitro-isophthalic acid dimethyl ester 
• 88-89-1 2,4,6-Trinitrophenol 
• 71932-29-1 4-acetoxy-isophthalic acid dimethyl ester 
• 100610-46-6 N-butyl-4-hydroxy-isophthalamic acid methyl ester 

Relevant academic research and scientific papers

Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors

Herein, a series of 2,3-dihydrobenzofurans have been developed as highly potent bromo and extra-terminal domain (BET) inhibitors with 1000-fold selectivity for the second bromodomain (BD2) over the first bromodomain (BD1). Investment in the development of two orthogonal synthetic routes delivered inhibitors that were potent and selective but had raised in vitro clearance and suboptimal solubility. Insertion of a quaternary center into the 2,3-dihydrobenzofuran core blocked a key site of metabolism and improved the solubility. This led to the development of inhibitor 71 (GSK852): a potent, 1000-fold-selective, highly soluble compound with good in vivo rat and dog pharmacokinetics.

BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS

The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.

4-hydroxyisophthalic acid derivative and synthesis method thereof

The invention discloses a 4-hydroxyisophthalic acid derivative and a synthesis method thereof, and belongs to the field of organic chemistry. The 4-hydroxyisophthalic acid derivative is a novel compound of a 5-bromo-4-hydroxyisophthalamide compound synthesized by using 4-hydroxyisophthalic acid as raw materials. According to the synthesis method, the derivative is prepared by using the 4-hydroxyisophthalic acid as raw materials through the steps of methyl esterification, bromination, hydrolysis, amidation and the like; the preparation method is simple; the compound structure is novel. Biological activity test shows that high tumor cell inhibitory activity is realized.

Design and Synthesis of a Series of l-trans-4-Substituted Prolines as Selective Antagonists for the Ionotropic Glutamate Receptors Including Functional and X-ray Crystallographic Studies of New Subtype Selective Kainic Acid Receptor Subtype 1 (GluK1) Antagonist (2S,4R)-4-(2-Carboxyphenoxy)pyrrolidine-2-carboxylic Acid

Ionotropic glutamate receptor antagonists are valuable tool compounds for studies of neurological pathways in the central nervous system. On the basis of rational ligand design, a new class of selective antagonists, represented by (2S,4R)-4-(2-carboxyphenoxy)pyrrolidine-2-carboxylic acid (1b), for cloned homomeric kainic acid receptors subtype 1 (GluK1) was attained (Ki = 4 μM). In a functional assay, 1b displayed full antagonist activity with IC50 = 6 ± 2 μM. A crystal structure was obtained of 1b when bound in the ligand binding domain of GluK1. A domain opening of 13-14° was seen compared to the structure with glutamate, consistent with 1b being an antagonist. A structure-activity relationship study showed that the chemical nature of the tethering atom (C, O, or S) linking the pyrrolidine ring and the phenyl ring plays a key role in the receptor selectivity profile and that substituents on the phenyl ring are well accommodated by the GluK1 receptor.

Tandem buildup of complexity of aromatic molecules through multiple successive electrophile generation in one pot, controlled by varying the reaction temperature

While some sequential electrophilic aromatic substitution reactions, known as tandem/domino/cascade reactions, have been reported for the construction of aromatic single skeletons, one of the most interesting and challenging possibilities remains the one-pot build-up of a complex aromatic molecule from multiple starting components, i.e., ultimately multi-component electrophilic aromatic substitution reactions. In this work, we show how tuning of the leaving group ability of phenolate derivatives from carbamates and esters provides a way to successively generate multiple unmasked electrophiles in a controlled manner in one pot, simply by varying the temperature. Here, we demonstrate the autonomous formation of up to three bonds in one pot and formation of two bonds arising from a three-component electrophilic aromatic substitution reaction. This result provides a proof-of-concept of our strategy applicable for the self-directed construction of complex aromatic structures from multiple simple molecules, which can be a potential avenue to realize multi-component electrophilic aromatic substitution reactions.

1D, 2D and 3D liquid crystalline phases formed by bent-core mesogens

The type of the mesophase is altered by a small change in the molecular architecture, i.e. increasing the number of alkyl chains attached to the mesogenic core at terminal positions. Lamellar (1D) and columnar (2D) phases are formed for molecules with one and three terminal chains, respectively. For those with two chains 3D phases are observed with either cubic or triclinic symmetry structure.

Synthesis and characterization of related substances of deferasirox, an iron (Fe3+) chelating agent

Deferasirox is an orally active iron chelating agent, and during process development for deferasirox, we observed six related substances (impurities), namely deferasirox methyl ester, deferasirox salicylyl derivative, deferasirox ethyl ester, deferasirox methoxy carbonyl derivative, bis(salicyl)imide, and deferasirox-2-isomer. The present work describes the detection, origin, synthesis, and characterization of these related substances.

COMPOUNDS CONTAINING FUSED RINGS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.

Ester derivatives and medicinal use thereof

The present invention relates to an ester represented by the formula [1]: or its pharmaceutically acceptable salt, or use of the same. The compound represented by the formula [1] or its pharmaceutically acceptable salt is useful as an agent for the treatment or prophylaxis of hyperlipidemia or the like, since it disappears very rapidly in the living body and has an excellent MTP inhibitory activity.

Isophthalic acid derivatives as matrix metalloproteinase inhibitors

Selective MMP-13 inhibitors are isophthalic acid derivatives of the formula wherein: R1, R2, and R3 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3; E is independently O or S; A and B independently are OR4 or NR4R5; each R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is 0 to 6; or a pharmaceutically acceptable salt thereof. The compounds are useful for treating diseases in a mammal that are mediated by MMP enzymes.